|
rs17069665
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The effects of rs17</span>069665 on ALL risk were more predominant in males and children < 10 years, and patients with lower rates of platelet or neutrophil.
|
31691337 |
2020 |
|
rs9400241
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found rs17069665 related to the increased ALL risk (OR = 1.76; 95% CI = 1.02-3.04), rs9400241 related to decreased ALL risk (OR = 0.80; 95% CI = 0.64-0.99).
|
31691337 |
2020 |
|
rs111978267
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We examined whether the common IKZF1 polymorphisms rs4132601 T/G and rs111978267 A/G are associated with ALL among a Tunisian pediatric cohort.
|
31604453 |
2019 |
|
rs2043211
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, NF-κB-94 ins/del ATTG and CARD8 (rs2043211) genotypes might serve as novel biomarkers and potential targets for ALL.
|
31428046 |
2019 |
|
rs2413739
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The aim of the study was to validate the impact of the single-nucleotide polymorphism rs2413739 (T > C) in the PACSIN2 gene on thiopurines pharmacological parameters and clinical response in an Italian cohort of pediatric patients with acute lymphoblastic leukemia (ALL) and inflammatory bowel disease (IBD).
|
31792371 |
2019 |
|
rs3758149
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The present study aimed to investigate the role of rs3758149 C/T polymorphism and transcription factors in the regulation of <i>GGH</i> expression in human acute lymphoblastic leukemia (ALL) CEM/C1 cells.
|
31739835 |
2019 |
|
rs4846049
|
|
|
0.010 |
GeneticVariation |
BEFREE |
MTHFR rs4846049 polymorphism may be associated with increased risk of childhood with ALL and MTHFR mRNA expression.
|
31737664 |
2019 |
|
rs543412
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our study suggested that there was significant association between the polymorphisms in miR-100 (rs543412) and decreased susceptibility to childhood ALL.
|
30848099 |
2019 |
|
rs57095329
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Haplotype analysis indicated a combination of allele A of rs57095329 and allele G of rs2910164 could represent a risk haplotype and an allele combination of G of rs57095329 and G of rs2910164 could represent a protective haplotype for ALL.
|
30576465 |
2019 |
|
rs1138272
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Conclusions Our results have shown that NR3C1 rs6198 variant and GSTP1 rs1695-rs1138272 haplotype are the most promising pharmacogenomic markers of GC response in ALL patients.
|
30210047 |
2018 |
|
rs1188383936
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Samples collected prior to the start of ALL therapy were evaluated for genetic and acquired PDs (proteins C and S, antithrombin, procoagulant factors VIII (FVIII:C), IX, XI and von Willebrand factor antigen levels, gene polymorphisms of factor V G1691A, prothrombin gene G20210A and methylene tetrahydrofolate reductase C677T, anticardiolipin antibodies, fasting lipoprotein(a), and homocysteine).
|
29334169 |
2018 |
|
rs12402181
|
|
|
0.010 |
GeneticVariation |
BEFREE |
SNPs rs12402181 in miR-3117 and rs62571442 in miR-3689d2 were associated with ALL risk in both cohorts, possibly through their effect on MAPK signalling pathway.
|
29796161 |
2018 |
|
rs153109
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, the association of IL-27 rs153109 and rs17855750 polymorphisms with risk of ALL development and their impact on EFS suggested an important role for this cytokine in biology and response to ALL therapy.
|
28828696 |
2018 |
|
rs17855750
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, the association of IL-27 rs153109 and rs17855750 polymorphisms with risk of ALL development and their impact on EFS suggested an important role for this cytokine in biology and response to ALL therapy.
|
28828696 |
2018 |
|
rs17863783
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Currently, pharmacogenomic testing of all childhood cancer patients with an indication for doxorubicin or daunorubicin therapy for RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 variants is recommended.
|
29713898 |
2018 |
|
rs1799796
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<i>XRCC3</i> rs1799794, rs45603942, rs1799796, and rs861530 were not significantly associated with the risk of childhood ALL in the Taiwanese population.
|
30532590 |
2018 |
|
rs2069762
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The purpose of this work was to explore the association of IFNG +874 A/T (rs2430561) and IL2 -330 G/T (rs2069762) SNPs with ALL susceptibility and/or protection in 488 Mexican Mestizos patients, as compared to 950 Mexican Mestizo healthy controls.
|
30212785 |
2018 |
|
rs2229774
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Currently, pharmacogenomic testing of all childhood cancer patients with an indication for doxorubicin or daunorubicin therapy for RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 variants is recommended.
|
29713898 |
2018 |
|
rs2430561
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The purpose of this work was to explore the association of IFNG +874 A/T (rs2430561) and IL2 -330 G/T (rs2069762) SNPs with ALL susceptibility and/or protection in 488 Mexican Mestizos patients, as compared to 950 Mexican Mestizo healthy controls.
|
30212785 |
2018 |
|
rs2853542
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We analyzed the presence of a 28-base pair tandem repeat (rs34743033; 2R3R), a single nucleotide polymorphism present within the 28-base pair repeat on the 3R allele (rs2853542; 3RG>C) and a 6-base pair deletion (rs15126436; TTAAAG) within the TYMS gene in germline DNA of 117 pediatric patients with ALL.
|
30222710 |
2018 |
|
rs34009635
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our findings suggest that the polymorphisms at MMP-8 -799C/T, Val436Ala and Lys460Thr may not play a major role in determining the personal susceptibility to childhood ALL in Taiwan.
|
29102926 |
2018 |
|
rs35866072
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our findings suggest that the polymorphisms at MMP-8 -799C/T, Val436Ala and Lys460Thr may not play a major role in determining the personal susceptibility to childhood ALL in Taiwan.
|
29102926 |
2018 |
|
rs4149009
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Genotyping for SLCO1A2 rs4149009 G > A in 141 children with ALL was performed using the Sequenom MassARRAY system.
|
29306656 |
2018 |
|
rs4646450
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP3A5 rs4646450 TT was 17% among ALL cases with FS lower than 28, and 3% in ALL patients without pathological FS (p = 5.60E-03; OR = 6.94 (1.76-27.39)).
|
29970035 |
2018 |
|
rs6198
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Conclusions Our results have shown that NR3C1 rs6198 variant and GSTP1 rs1695-rs1138272 haplotype are the most promising pharmacogenomic markers of GC response in ALL patients.
|
30210047 |
2018 |